Glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have emerged as a promising therapeutic option beyond their established role in managing type 2 diabetes mellitus (T2DM) and obesity. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.